Dimethyl fumarate and its esters: A drug with broad clinical utility?

Stephanie Kourakis; Cara A. Timpani; Judy B. de Haan; Nuri Gueven; Dirk Fischer; Emma Rybalka

doi:10.3390/ph13100306

Dimethyl fumarate and its esters: A drug with broad clinical utility?

Stephanie Kourakis, Cara A. Timpani, Judy B. de Haan, Nuri Gueven, Dirk Fischer, Emma Rybalka

Research output: Contribution to journal › Review Article › Research › peer-review

57 Citations (Scopus)

Abstract

Fumaric acid esters (FAEs) are small molecules with anti‐oxidative, anti‐inflammatory and immune‐modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing‐Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune‐mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first‐line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated.

Original language	English
Article number	306
Number of pages	15
Journal	Pharmaceuticals
Volume	13
Issue number	10
DOIs	https://doi.org/10.3390/ph13100306
Publication status	Published - Oct 2020
Externally published	Yes

Keywords

Clinical application
Dimethyl fumarate
Disease
Fumaric acid esters
Inflammation
Nrf2
Oxidative stress

Access to Document

10.3390/ph13100306Licence: CC BY

Cite this

@article{bcfbb96ae2374252a02a1e5ee9a8b864,

title = "Dimethyl fumarate and its esters: A drug with broad clinical utility?",

abstract = "Fumaric acid esters (FAEs) are small molecules with anti‐oxidative, anti‐inflammatory and immune‐modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing‐Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune‐mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first‐line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated.",

keywords = "Clinical application, Dimethyl fumarate, Disease, Fumaric acid esters, Inflammation, Nrf2, Oxidative stress",

author = "Stephanie Kourakis and Timpani, {Cara A.} and {de Haan}, {Judy B.} and Nuri Gueven and Dirk Fischer and Emma Rybalka",

year = "2020",

month = oct,

doi = "10.3390/ph13100306",

language = "English",

volume = "13",

journal = "Pharmaceuticals",

issn = "1424-8247",

publisher = "MDPI AG",

number = "10",

}

TY - JOUR

T1 - Dimethyl fumarate and its esters

T2 - A drug with broad clinical utility?

AU - Kourakis, Stephanie

AU - Timpani, Cara A.

AU - de Haan, Judy B.

AU - Gueven, Nuri

AU - Fischer, Dirk

AU - Rybalka, Emma

PY - 2020/10

Y1 - 2020/10

N2 - Fumaric acid esters (FAEs) are small molecules with anti‐oxidative, anti‐inflammatory and immune‐modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing‐Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune‐mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first‐line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated.

AB - Fumaric acid esters (FAEs) are small molecules with anti‐oxidative, anti‐inflammatory and immune‐modulating effects. Dimethyl fumarate (DMF) is the best characterised FAE and is approved and registered for the treatment of psoriasis and Relapsing‐Remitting Multiple Sclerosis (RRMS). Psoriasis and RRMS share an immune‐mediated aetiology, driven by severe inflammation and oxidative stress. DMF, as well as monomethyl fumarate and diroximel fumarate, are commonly prescribed first‐line agents with favourable safety and efficacy profiles. The potential benefits of FAEs against other diseases that appear pathogenically different but share the pathologies of oxidative stress and inflammation are currently investigated.

KW - Clinical application

KW - Dimethyl fumarate

KW - Disease

KW - Fumaric acid esters

KW - Inflammation

KW - Nrf2

KW - Oxidative stress

UR - http://www.scopus.com/inward/record.url?scp=85092456622&partnerID=8YFLogxK

U2 - 10.3390/ph13100306

DO - 10.3390/ph13100306

M3 - Review Article

C2 - 33066228

AN - SCOPUS:85092456622

SN - 1424-8247

VL - 13

JO - Pharmaceuticals

JF - Pharmaceuticals

IS - 10

M1 - 306

ER -

Dimethyl fumarate and its esters: A drug with broad clinical utility?

Abstract

Keywords

Access to Document

Other files and links

Cite this